Evidence and gaps in clinical outcomes of novel pharmacologic therapies for sickle cell disease: A systematic literature review highlighting insights from clinical trials and real-world studies [0.03%]
新型药理学疗法治疗镰状细胞病的临床疗效证据及缺口：系统文献回顾揭示了临床试验和真实世界研究的见解
Mohamed Yassin,Caterina Minniti,Nirmish Shah et al.
Mohamed Yassin et al.
This systematic review aims to summarise the clinical outcomes of l-glutamine, crizanlizumab, and voxelotor in the treatment of sickle cell disease (SCD) based on clinical trials and real-world data and to identify any gaps in the observati...
Practical guidance on the prevention and management of infection in multiple myeloma patients: A case-based approach [0.03%]
基于病例的指导：预防和管理多发性骨髓瘤患者的感染
A Kannan,K Jeffrey,S Misbah et al.
A Kannan et al.
The risk of infection in multiple myeloma patients is significant, due to immune dysfunction secondary to myeloma, immunosenescence and age-related comorbidities, given the elderly myeloma patient demographic. Newer treatments, despite prov...
Transplant-acquired allergy in HCT-recipients: Reference for clinical management [0.03%]
造血干细胞移植受者移植后过敏反应的临床诊治参考标准
Akihiro Ohmoto,Yoshiyuki Yamada,Shigeo Fuji
Akihiro Ohmoto
Transplant-acquired allergy (TAA) is well known in pediatric patients undergoing liver transplantation. Regarding allogeneic hematopoietic cell transplantation (allo-HCT), the clinical characteristics of TAA have not been fully elucidated. ...
Navigating acute myeloid leukemia towards better outcomes: Treatment pathways and challenges for patients ineligible for intensive chemotherapy [0.03%]
向更好的疗效迈进：适于不适合强化化疗的急性髓系白血病患者的治疗途径和挑战
Raffaele Palmieri,Anna Candoni,Francesco Di Raimondo et al.
Raffaele Palmieri et al.
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy that affects primarily older individuals. Patients ineligible to receive intensive standard chemotherapy followed by consolidation with/without hematopoietic stem cell tra...
Neutrophils in BCR::ABL1 negative MPN: Contributors or bystanders of fibrosis? [0.03%]
BCR::ABL1阴性MPN中的中性粒细胞：纤维化的贡献者还是旁观者？
Gaël Vermeersch,Mieke Gouwy,Paul Proost et al.
Gaël Vermeersch et al.
BCR::ABL1 negative myeloproliferative neoplasms (MPNs) are a heterogenous group of disorders characterized by clonal proliferation of hematopoietic stem and progenitor cells (HSPCs) within the bone marrow. Although the identification of som...
Haploidentical transplantation: An optimal platform for graft manipulation and cellular therapies [0.03%]
单倍型移植：移植物操作和细胞治疗的理想平台
C C Astigarraga,Klauberg Mpms,L Iovino et al.
C C Astigarraga et al.
Allogeneic hematopoietic stem cell transplantation (allo-HCT) remains a curative therapeutic option for patients with high-risk hematologic malignancies. When a fully matched donor is unavailable, haploidentical hematopoietic stem cell tran...
Low flow: Selecting a limited flow cytometry panel where resources are constrained [0.03%]
低流量：在资源有限的情况下选择限定的流式细胞术面板
Ailie Ross,Donna Rudd,Joel Wight
Ailie Ross
Diagnosis and treatment of patients with haematological malignancies (HM) is hampered by access to pathology services in resource-limited settings (RLS). Internationally accepted guidelines and diagnostic criteria for HM require access to s...
Bridging the evidence-to-practice gap: Advancing neonatal blood transfusion. A narrative review of recent guidelines [0.03%]
缩小证据到实践的差距：推进新生儿输血。近期指南的故事回顾
Rozeta Sokou,Eleni A Gounari,Andreas G Tsantes et al.
Rozeta Sokou et al.
Neonates represent a distinct population within the context of transfusion medicine. Blood transfusions in neonates are vital interventions for multiple conditions, despite their inherent risks and potential complications. Differences in ph...
Nishaka William,Jason P Acker
Nishaka William
The global infrastructure supporting nearly 100 million transfusions annually relies on the ability to store red cell concentrates (RCCs) for up to 42 days at hypothermic temperatures or indefinitely at low sub-zero temperatures. While thes...
BTK inhibitors resistance in B cell malignancies: Mechanisms and potential therapeutic strategies [0.03%]
B细胞恶性肿瘤中BTK抑制剂的耐药性：机制及潜在治疗策略
Xin Liu,Yufan Lin,Qiqi Zhuang et al.
Xin Liu et al.
Bruton tyrosine kinase inhibitors (BTKi) have shown prominent clinical efficacy in patients with B cell malignancies, such as chronic lymphocytic leukemia, mantle cell lymphoma, diffuse large B cell lymphoma, and Waldenström's macroglobuli...